benralizumab sold brand name fasenra monoclonal antibody directed alpha chain receptor developed medimmune treatment two phase iii clinical trials benralizumab reported meeting primary endpoints approved us food drug administration november treatment severe eosinophilic granted designation orphan drug food drug administration treatment eosinophilic oesophagitis august common adverse effects include injection site reactions reported patients vs placebo clinical immune activation dostarlimab ibalizumab monoclonal article stub help wikipedia expanding drug article relating respiratory system stub help wikipedia expanding ithttpsenwikipediaorgwikibenralizumab